— AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) reported a net loss of $23.62 million or $0.70 per share for the third quarter of 2019, vs. $0.66 per share loss expected
— Revenues dropped to $84.13 million from $122.24 million last year, vs. $88.27 million expected
— Lowered full-year 2019 revenue guidance to $320-$330 million from the earlier outlook of $325-$355 million
— Expects full-year operating loss of $278-$268 million, up from $276 million loss estimated earlier
— Expects adjusted EBITDA loss in the range of $75 million to $65 million for 2019, which is down from the previous forecast of $85-$75 million